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Human immunodeficiency virus (HIV) persists indefinitely in individuals with HIV who 
receive antiretroviral therapy (ART) owing to a reservoir of latently infected cells that 
contain replication-competent virus1–4. Here, to better understand the mechanisms 
responsible for latency persistence and reversal, we used the interleukin-15 
superagonist N-803 in conjunction with the depletion of CD8+ lymphocytes in  
ART-treated macaques infected with simian immunodeficiency virus (SIV). Although 
N-803 alone did not reactivate virus production, its administration after the depletion 
of CD8+ lymphocytes in conjunction with ART treatment induced robust and 
persistent reactivation of the virus in vivo. We found viraemia of more than 60 copies 
per ml in all macaques (n = 14; 100%) and in 41 out of a total of 56 samples (73.2%) that 
were collected each week after N-803 administration. Notably, concordant results 
were obtained in ART-treated HIV-infected humanized mice. In addition, we observed 
that co-culture with CD8+ T cells blocked the in vitro latency-reversing effect of N-803 
on primary human CD4+ T cells that were latently infected with HIV. These results 
advance our understanding of the mechanisms responsible for latency reversal and 
lentivirus reactivation during ART-suppressed infection.
HIV remains a major global health problem, leading to approximately 
1.1 million deaths worldwide annually5. Despite the major declines in 
morbidity and mortality associated with the use of ART, there is neither 
a vaccine nor a cure for HIV infection. The inability to eradicate HIV 
infection with the current therapies is due to the presence of latently 
infected cells that contain integrated replication-competent virus 
that persist indefinitely in HIV-infected individuals undergoing ART 
and contribute to rebound viraemia when therapy is discontinued 
(that is, the viral reservoir)1–4. A key paradigm in the field of HIV cure—
referred to as ‘shock and kill’6,7—supposes that the induction of virus 
expression (that is, ‘virus reactivation’) in these latently infected cells 
(‘shock’) followed by immune-mediated clearing (‘kill’) may substan-
tially reduce the reservoir size and possibly lead to a functional cure 
for HIV infection. Unfortunately, no latency-reversing agent (LRA) 
tested to date has successfully perturbed the viral reservoir in clinical 
trials in humans. In particular, histone deacetylase inhibitors have not 
induced either robust virus reactivation or reduction of the viral reser-
voir in ART-treated HIV-infected individuals8–12. More encouragingly, 
in SIV-infected ART-treated rhesus macaques (Macaca mulatta), treat-
ment with toll-like receptor 7 (TLR7) agonists was linked to transient 
blips of plasma viraemia13. However, this result was not reproduced in 
further studies14,15. More recently, persistent remission was observed 
in a subset of ART-treated simian–human chimeric immunodeficiency 
virus (SHIV)-infected macaques that received the TLR7 agonist GS-9620 
in combination with the broadly neutralizing PGT121 antibody16. In all, 
these published data indicate that novel, more potent approaches 
for latency reversal are needed to achieve a functional cure for HIV 
infection.
SIV and SHIV infection of rhesus macaques
Infection of rhesus macaques with SIV or SHIV is the most widely used 
animal model for the study of the mechanisms by which the viral res-
ervoir is established and maintained under ART and to preclinically 
test interventions aimed at reducing the viral reservoir in vivo17. A pre-
vious study demonstrated that the depletion of CD8+ lymphocytes 
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in SIV-infected ART-treated macaques was consistently followed by 
increased plasma viraemia, thus indicating that these cells contribute 
to viral suppression under ART18. Although the precise mechanisms 
responsible for this observation remain unclear, phylogenetic analysis 
of the rebounding virus suggested that silencing of virus transcription 
contributes to this antiviral effect. On the basis of these observations, 
we hypothesized that the depletion of CD8+ lymphocytes combined 
with LRAs may enhance virus production under ART. As shown in Fig. 1a, 
the IL-15 superagonist N-803 is a complex of a mutant IL-15 and a dimeric 
IL-15 receptor αSu/Fc fusion protein19. The engineered structure is at 
least 25 times more biologically potent than IL-15 as it mimics transpre-
sentation, and the IgG–Fc component confers improved in vivo safety 
and bioavailability20,21. In the setting of ART-suppressed lentiviral infec-
tion, N-803 may target the residual virus pool through its ability to 
act in vitro as a potent LRA and to strengthen the antiviral immune 
responses mediated by T and natural killer (NK) cells22.
The current study included a total of 35 SIV-infected macaques that 
started ART at day 56 after infection and were treated for at least 1 year 
before any further intervention. The macaques were divided in three 
groups as follows (Fig. 1b): 7 macaques were treated with 4 weekly doses 
of 100 μg kg−1 of N-803 (group 1, N-803 alone), 14 macaques received 1 
dose of the CD8-depleting antibody, MT807R1 (anti-CD8α) at 50 mg kg−1 
intravenously (group 2, CD8 depletion alone) and 14 macaques received 
4 weekly doses of N-803 starting at the time of CD8 depletion (group 3, 
CD8 depletion with N-803). After reconstitution of CD8+ T cells (defined 
as more than 100 CD8+ T cells per μl of blood), 7 macaques in groups 2 
and 3 received four additional weekly administrations of N-803. Periph-
eral blood samples, lymph node and rectal biopsies were collected 
at various time points before, during and after these interventions. 
All macaques underwent analytical treatment interruption at week 3 
after either CD8+ T cell reconstitution or the last N-803 treatment. As 
shown in Fig. 1c, all macaques showed suppression of viraemia after 
1 year of ART, with plasma viral loads below the detectable limit of 
our standard assay (60 copies per ml of plasma)23 at the time of the 
additional interventions in 33 out of 35 macaques (94.3%). We also 
measured residual plasma viraemia using an ultrasensitive assay (limit 
of detection of 3 copies per ml)24–26 at three monthly sampling points 
before the interventions. Viraemia was below 3 copies per ml in 19 out 
of 35 ART-treated macaques (52.3%), and 26 out of 35 macaques (74.3%) 
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Fig. 1 | Study design and phenotypic and transcriptomic effects of N-803 
with or without CD8 depletion in rhesus macaques. a, IL-15 superagonist 
N-803 structure. i.v., intravenous; TCID50, 50% tissue-culture infectious dose. 
b, Study design. Arrows indicate the administration of 100 μg kg−1 N-803 
(green) and 50 mg kg−1 MT807R1 (blue). c, Plasma viral load pre-intervention 
(n = 35 macaques), including infection and initiation of ART (grey bar). Limit of 
detection is 60 copies of SIV RNA per ml of plasma (black bar). d, Mean 
peripheral CD4+ T cell (maroon), CD8+ T cell (purple) and NK cell (grey) count in 
the lymph node. e, Percentage of CD4+ and CD8+ T cells in the lymph node. 
f, Ki-67 expression in cellular subsets after intervention with N-803 
(n = 7 macaques). g, Ki-67 expression in bulk CD4+ T cells after treatment with 
only N-803 (green, n = 7 macaques), CD8 depletion alone (blue, 
n = 14 macaques), and CD8 depletion combined with the administration of 
N-803 (red, n = 14 macaques). h, Gene-set enrichment analysis of RNA-
sequencing data from bulk CD4+ T cells comparing gene sets enriched on day 3 
after intervention with N-803 alone (green, n = 7 macaques), CD8 depletion 
alone (blue, n = 7 macaques) or CD8 depletion combined with N-803 treatment 
(red, n = 7 macaques). i, Heat map of the enriched genes in bulk CD8+ T cells in 
the IL-2 and STAT-5 signalling gene set after administration of N-803 alone 
(n = 7 macaques). Data are mean ± s.e.m. Two-sided Kruskal–Wallis tests (d, f) 
and Friedman tests (e, g) were used to compare values after the interventions 
to the pre-intervention baseline and approximate P-value summaries are 
provided.
of IL-15 signalling, as the receptor for this cytokine shares two out of 
three subunits with IL-2 and uses STAT-5 as the key adaptor molecule 
(Fig. 1i). In addition, we examined the expression of 25 genes specifi-
cally involved in the host–virus interaction during SIV infection and 
found that N-803 administration induced a consistent and transient 
upregulation of APOBEC3 in CD4+ T cells, CD8+ T cells and NK cells 
(Extended Data Fig. 3a–c).
As shown in Fig. 2a and Extended Data Table 1, administration of 
N-803 was not associated with an increase of plasma viraemia of 
>60 copies per ml in any of the treated macaques, indicating that the 
IL-15 superagonist is not sufficient to exert an in vivo LRA effect in ART-
treated SIV-infected macaques when used alone. As expected on the
basis of previous studies18, macaques undergoing CD8 depletion alone
showed a moderate but significant increase in virus production, with 
plasma viraemia of >60 copies per ml detected in 11 out of 14 macaques 
(78.6%) and 18 out of 56 samples (32.1%) collected weekly after CD8 
depletion (Fig. 2b). Viraemia of >1,000 copies per ml was observed in 
2 out of 14 macaques (14.2%) and 2 out of 56 (3.6%) of the same samples 
(Fig. 2b). In all cases, the level of virus production returned to below 
60 copies per ml of plasma at the time of CD8+ T cell reconstitution
(Fig. 2e). Overall, the level of increased viraemia observed in this study 
was consistent with previous studies18, even though the magnitude of 
virus production after CD8 depletion was slightly less marked, possibly 
related to the longer period of ART treatment (12 months compared 
with 2–8 months)18. Notably, macaques treated with N-803 during
CD8 depletion showed highly robust and persistent levels of virus 
production, with viraemia of >60 copies per ml detected in 14 out of 
14 macaques (100%) and 41 out of 56 samples (73.2%) and viraemia of 
>1,000 copies per ml observed in 6 out of 14 macaques (42.9%) and 
13 out of 56 samples (23.2%) (Fig. 2c). We emphasize that all seven 
macaques with full suppression of virus production at the time of 
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Fig. 2 | SIV and HIV reactivation after CD8 depletion combined with N-803 
treatment. a–c, Plasma viral loads after intervention with N-803 alone 
(n = 7 macaques) (a), CD8 depletion alone (n = 14 macaques) (b) or CD8 
depletion combined with N-803 (n = 14 macaques) (c). d, Longitudinal plasma 
viral loads for macaques with fully suppressed viral load (<3 copies per ml of 
plasma) before CD8 depletion combined with administration of N-803.  
e, f, Comparison of viral load pre-intervention (pre), post-intervention when 
CD8+ T cells are <100 cells per μl blood (post) and during CD8+ T cell 
reconstitution >100 cells per μl blood (CD8 return) in macaques that  
underwent CD8 depletion alone (n = 14 macaques) (e) or CD8 depletion with 
N-803 (n = 14 macaques) (f). Data are mean ± s.e.m. g, Plasma viral loads after 
CD8 depletion with N-803 administration in SHIVSF162P3-infected macaques 
intervention (Extended Data Table 1). These results indicate that the 
level of virus suppression observed in our cohort of macaques was in 
most cases comparable to that of long-term ART-treated HIV-infected 
individuals27–29.
As shown in Extended Data Fig. 1a–d and consistent with previous 
studies18,30, treatment with anti-CD8α MT807R1, with or without N-803, 
depleted on average 99.1% of CD3+CD8+ T cells in peripheral blood, 
97.9% in lymph nodes and 99.5% in rectal biopsies. In addition, treatment 
with MT807R1 alone depleted 93.2% of NK cells in peripheral blood 
(Extended Data Fig. 1e). As expected on the basis of previous studies, 
N-803 administration alone resulted in the expansion of CD8+ T cells 
in the blood and lymph nodes (Fig. 1d, e), as well as increased prolifera-
tion of peripheral CD8+ T cells, CD4+ T cells and NK cells (Fig. 1f). Of 
note, although CD8 depletion alone did not result in a rapid increase 
in CD4+ T cell proliferation (as measured by Ki-67 expression), the 
combination of CD8 depletion and treatment with N-803 led to a sig-
nificant increase in CD4+ T cell proliferation (Fig. 1g and Extended Data 
Fig. 2r–v). The frequency of CD4+ T cells co-expressing Ki-67 and the 
HIV and SIV coreceptor CCR5—potential target cells for infection—was 
significantly increased across all groups by the third week after inter-
vention (Extended Data Fig. 2l). Additionally, CD8 depletion with or 
without N-803 administration resulted in the expansion of effector 
memory CD4+ T cells and increased PD-1 expression on CD4+ T cells 
(Extended Data Fig. 2f, g).
To better characterize the biological effects of N-803, we conducted 
a transcriptional analysis using RNA sequencing of sorted CD4+ T cells 
collected before intervention and day 3, week 2 and week 4 after the 
start of intervention. Regardless of concurrent CD8 depletion, N-803 
induced a significant upregulation of gene sets associated with cell 
cycling and proliferation, activation, antiviral responses and cell signal-
ling (Fig. 1h). In CD8+ T cells, N-803 resulted in significant enrichment of 
genes in the IL-2 and STAT-5 signalling gene set, which is also 
indicative 
after 6 months of ART (n = 5 macaques). Viral suppression of <60 copies per ml 
is shown as a black bar (a–d, g) or dashed line (e, f) and the limit of detection for 
these assays was 3 copies per ml of plasma. h, RNAscope determination of the 
percentage of SIV RNA+ lymph node cells expressing high levels (>4 copies) of 
viral RNA per cell 1 week after CD8 depletion combined with N-803 treatment. 
i–k, Plasma viral loads of HIV-infected, ART-treated humanized mice treated 
with N-803 alone (green, n = 7 mice) (i), CD8 depletion alone (blue, n = 8 mice) 
( j) or CD8 depletion with N-803 administration (red, n = 8 mice) (k). The limit of 
detection was 346 copies per ml. Statistical significance was calculated using a 
two-sided Kruskal–Wallis test (e, f) or Wilcoxon signed-rank test (h). A key for 
the macaque ID codes is provided in Extended Data Fig. 5.
repeated viral load measurements <3 copies per ml of plasma) dem-
onstrated clear virus reactivation with detectable levels in 26 out of 
28 time points 1 week after each N-803 administration, and >60 cop-
ies per ml in 16 out of 28 of the same samples (Fig. 2d). Similar results 
were obtained in a smaller pilot study in which N-803 administration 
during CD8 depletion was performed in five ART-suppressed SHIVSF162P3-
infected macaques (Fig. 2g). The level of viraemia observed in SIV-
infected macaques treated with combined CD8 depletion and N-803 
administration during long-term ART is higher and more persistent 
than the results of previous shock-and-kill cure strategies tested in 
humans and nonhuman primates8–13,31.
After the last treatment with N-803, the level of viraemia rapidly 
decreased coincident with the reconstitution of CD8+ T cells, and all 
macaques returned to <60 copies per ml by week 6 after CD8 deple-
tion and N-803 administration (Fig. 2c, f). As expected, CD8+ T cell 
reconstitution was faster in CD8-depleted macaques co-treated with 
N-803 (Extended Data Fig. 5e–g), as the IL-15 superagonist enhances
CD8+ T cell proliferation (Fig. 1d–f).
We next investigated the correlates of virus reactivation in ART-
treated SIV-infected macaques that underwent CD8 depletion with 
N-803, and observed that the post-depletion viral load (day 3 to week 6) 
was negatively correlated with the frequency of peripheral CD8+ T cells
(Extended Data Fig. 5b). Additionally, the area under the curve of virus 
production during CD8 depletion and administration of N-803 was 
directly correlated with pre-intervention viraemia (Extended Data 
Fig. 5d). Of note, no correlation was found between the level of virus
production after CD8 depletion and/or N-803 treatment and either the 
size of the peripheral blood DNA reservoir (measured as the fraction 
of SIV DNA+CD4+ T cells) or the level of CD4+ T cell activation (meas-
ured as Ki-67 or PD-1 expression on CD4+ T cells) (data not shown). To 
assess whether combined CD8 depletion with N-803 administration 
induced SIV production in lymphoid tissues, we next analysed the levels 
of SIV RNA in the lymph nodes using the RNAscope technology at pre-
intervention and day 7 after intervention in 5 representative macaques 
that were both depleted of CD8+ lymphocytes and treated with N-803. 
As shown in Fig. 2h, and consistent with the measurements of plasma 
viraemia, we found a statistically significant increase in the percent-
age of SIV RNA+ cells with high levels of SIV RNA after intervention. 
No changes were observed in the level of SIV RNA in peripheral CD4+ 
T cells (Extended Data Fig. 4a–c), suggesting that lymphoid tissues are 
the main source of reactivated virus after the combined CD8 depletion 
and administration of N-803.
HIV infection of humanized mice
To confirm the virus reactivation induced by the combined depletion 
of CD8+ lymphocytes and administration of N-803 in SIV-infected ART-
treated macaques in an in vivo model using HIV, we next conducted 
a similarly designed experiment using bone-marrow–liver–thymus 
(BLT) humanized mice infected with HIV-1JR-CSF and treated with ART. 
As shown in Fig. 2i–k, HIV-infected humanized mice showed markedly 
similar results to those obtained in SIV-infected macaques, with no 
plasma virus reactivation after the administration of N-803 alone, a 
moderate level of virus reactivation after CD8 depletion alone, and a 
robust level of virus reactivation in 7 out of 8 (87.5%) humanized mice 
that were depleted of CD8+ lymphocytes and treated with N-803. Fur-
thermore, we also noted a statistically significant increase in the levels 
of cell-associated HIV RNA in the spleen and human-derived thymus of 
humanized mice that were depleted of CD8+ lymphocytes and treated 
with N-803 (Extended Data Fig. 6b).
CD8+ T cells inhibit latency reversal in vitro
The combined data obtained in SIV-infected macaques and HIV-infected 
humanized mice indicate that the strong virus reactivation activity 
attributed to N-803 is revealed only in the absence of CD8+ T cells, thus 
delineating a novel mechanism of latency maintenance and/or inhibi-
tion of latency reversal mediated by CD8+ lymphocytes. To recapitu-
late this observation in a reductionist in vitro model of HIV latency in 
human cells, we used the recently developed latency and reversal assay 
(LARA)32 to evaluate how CD8+ T cells affect the virus reactivation activ-
ity of N-803 in autologous memory CD4+ T cells latently infected with 
HIV89.6 (Fig. 3a). Of note, this assay was conducted using cells derived 
from HIV-negative donors, thus HIV-specific cytotoxic CD8+ T cells were 
absent. Whereas N-803 (and its biological counterpart, IL-15) reactivates 
HIV expression in latently infected CD4+ T cell monocultures, co-culture 
with activated CD8+ T cells significantly suppresses this ability (Fig. 3b). 
These data indicate that CD8+ T cells effectively suppress the latency-
reversing activity of N-803, and therefore confirm the discovery of a 
previously unrecognized CD8+ T-cell-mediated activity that contributes 
to the maintenance of lentivirus latency in vivo in primates.
Virus sequence analysis
To investigate the viral dynamics associated with reactivation after 
CD8 depletion and administration of N-803 in SIV-infected ART-treated 
macaques, we performed a longitudinal sequence analysis of plasma 
virus using single-genome PCR amplification of the SIVmac239-derived 
env genes. The viral env was sequenced at three pivotal time points: 
day 7 after infection (at peak viraemia), day 56 after infection—that 
is, immediately before ART initiation (pre-ART)—and during peak 
virus reactivation. We conducted this analysis in six macaques that 
showed robust virus reactivation (plasma viraemia of >800 copies 
per ml) (Fig. 2c). Extended Data Figure 7 shows phylogenetic analysis 































































































































Fig. 3 | In vitro co-culture of latently infected human CD4+ T cells with 
autologous CD8+ T cells results in decreased expression of HIV Gag during 
LRA administration. a, Schematic of HIV latency model. Memory CD4+ T cells 
(mCD4+) were enriched on day 0, infected in vitro on day 3 with HIV89.6 and 
maintained in saquinavir. On day 6, TGFβ, IL-7, conditioned medium from the 
H-80 feeder cell line and additional antiretroviral drugs were added to the 
culture. Cryopreserved autologous peripheral-blood mononuclear cells 
(PBMCs) were thawed on day 8 and rested overnight before enriching for total 
CD8+ (tCD8+) cells and then TCR-activated for 3 days. On day 12, HIV-infected 
mCD4+ and TCR-activated total CD8+ cells were co-cultured in a 1:1 or 1:5 ratio in 
the presence of anti-CD3/CD28 antibody, N-803 or recombinant IL-15 until day 
15. b, HIV Gag+CD4+ T cell frequency was quantified using flow cytometry and 
the frequency in co-cultures was calculated as a fold change compared to CD4 
T cell monoculture. Each colour represents a unique donor (n = 8 biologically
independent samples) and data are mean ± s.e.m. (indicated by the grey bars). 
Statistical significance was measured using a matched one-way analysis of 
variance (ANOVA).
performed an analytical treatment interruption in all macaques three 
weeks after either CD8 reconstitution and/or the last N-803 treatment. 
As shown in Fig. 4g–i, all macaques rebounded within three weeks of 
ART interruption and most macaques sustained high viral loads until 
the time of necropsy. It should be noted that in the current study, ART 
was initiated at day 56 after infection, thus substantially later than in 
other published macaque studies that included analytical treatment 
interruption, and thus in the setting of a larger and more-disseminated 
reservoir16,33. The rapid rebound after ART interruption was therefore 
not unexpected as the experimental design was focused on assessing 
the shock effect of CD8 depletion combined with N-803 administra-
tion, with no anticipated effect on the reservoir size in the absence of 
an intervention aimed at clearing the cells that have reactivated SIV 
production (kill phase of the shock-and-kill approach). The absence of 
a decrease in the level of SIV DNA+ cells after the combined CD8 deple-
tion and administration of N-803 may be due to the lack of CD8+ T-cell-
mediated clearance of cells that have reactivated virus expression and/
or the N-803-mediated proliferative expansion of infected CD4+ T cells 
that have survived the events of virus reactivation.
Discussion
The current paradigm for shock-and-kill interventions for an HIV cure 
suggests that reactivation of virus transcription in latently infected cells 
is the first essential step to eliminate the persistent reservoir of repli-
cation-competent virus in ART-treated HIV-infected individuals. In this 
study, we have shown that the administration of the IL-15 superagonist 
N-803 in both SIV-infected macaques and HIV-infected humanized mice 
induces a highly robust and persistent reversal of latency only in the set-
ting of CD8+ lymphocyte depletion, thus suggesting a substantial role 
for CD8+ lymphocytes in suppressing the LRA effect of N-803. Notably, 
this previously undescribed role of CD8+ lymphocytes in maintaining 
virus latency was fully reproduced in an in vitro experimental approach 
that involved the co-culture of activated, unprimed CD8+ T cells with 
autologous, latently HIV-infected human primary CD4+ T cells. Here
we use a novel approach to manipulate latently infected cells and have 
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Fig. 4 | CD8 depletion combined with N-803 administration does not 
decrease the size of the latent SIV viral reservoir. a–f, Copies of cell-
associated SIV DNA per 106 cells was determined in peripheral CD4+ T cells (a–c) 
and frozen bulk lymph node cells (d–f) in macaques treated with N-803 alone 
(n = 7 (a) and n = 3 (d) macaques), CD8 depletion alone (n = 14 (b) and n = 5 (e) 
macaques), and CD8 depletion with N-803 treatment (n = 14 (c) and n = 3 (f) 
macaques). Two-sided Friedman tests (a–c) and Wilcoxon signed-rank tests  
(d–f) were used to determine statistical significance between pre-treatment 
The peak viral load Env sequences were homogeneous and nearly 
identical to the input SIVmac239 sequence; however, the diversity and 
number of informative sites at subsequent time points were limited, 
such that sequences could not be clustered on the basis of time point 
with significant bootstrap support. The diversity at each time point, 
although limited, was quantified by determining the number of amino 
acid differences from the input SIVmac239 sequence. Extended Data Fig-
ure 8a shows that, for all macaques, the peak viraemia Env sequences 
are the least different from the input virus, as expected, and increased 
divergence was observed at the pre-ART time point and after reactiva-
tion. We next calculated the average number of amino acid differences 
from SIVmac239 at each time point, and compared these with contempo-
raneous plasma viraemia for each macaque in a correlation matrix. 
The only significant association was a direct relationship between Env 
divergence and plasma viraemia during reactivation (Extended Data 
Fig. 8b). Finally, Extended Data Fig. 9 shows the location of sequence 
changes at each time point using highlighter plots of the Env amino 
acid sequences. Overall, this analysis supports the hypothesis that CD8 
depletion and administration of N-803 induces robust reactivation of 
a diverse population of viral variants. As no signs of virus evolution 
emerged from the longitudinal sequence analysis during high levels 
of latency reversal, it is unlikely that the rebounding virus is a product 
of de novo viral replication. Supporting this hypothesis, the combined 
CD8 depletion and administration of N-803 did not increase the levels 
of two-long-terminal repeat circles—which are considered a marker 
of recent lentivirus infection—in peripheral-blood mononuclear cells 
(data not shown).
Analytic treatment interruption
To determine whether the interventions used induced a decrease 
in the virus reservoir, we first longitudinally measured the level of 
cell-associated SIV DNA in blood and lymph nodes. As shown in 
Fig. 4a–f, none of the experimental groups showed significant 
changes in either the total fraction of circulating CD4+ T cells or the 
calculated fraction of lymph-node-derived cells that contained SIV 
DNA. To functionally assess the effect of the treatment regimens on 
the reservoir size, we 
and post-treatment time points. For all comparisons, P > 0.05. Sample 
mean ± s.e.m. are indicated by grey bars. g–i, Viral rebound after interruption 
of ART (indicated by arrowheads) in macaques that received N-803 alone 
(n = 7 macaques) (g), CD8 depletion alone (n = 13 macaques) (h) or CD8 
depletion with N-803 (n = 14 macaques) (i). ATI, analytical treatment 
interruption. The limit of detection was <3 copies of SIV RNA per ml plasma. 
The black bar indicates viral loads <60 copies per ml and the grey box indicates 
ART.
most widely used in vivo models for HIV cure interventions and then 
recapitulated the results in an in vitro experimental system of virus 
latency. In addition to this conceptual advance, this study defines a 
robust shock approach that could provide a key experimental system to 
directly compare and contrast the efficacy of different kill interventions 
in vivo, including those that may act in a CD8+ T-cell-independent man-
ner (such as neutralizing antibodies, CD4 mimetics or immunotoxins). 
Further studies that aim to identify the specific molecular pathways 
used by CD8+ T cells to promote latency may allow the suppression of 
this activity, and therefore enable the full use of the virus-reactivating 
potential of N-803 or other LRAs in the clinical setting without deplet-
ing CD8+ lymphocytes.
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Methods
Rhesus macaques, SIV-infection, ART, CD8 depletion and 
administration of N-803
This study was conducted using a cohort of 35 Indian-origin rhesus 
macaques housed at Yerkes National Primate Research Center (male 
and female, 2–3 years of age at the start of the study). All macaques were 
Mamu*B07− and Mamu*B17−; the following macaques were Mamu*A01+: 
77_13, RFr15, 208_13, RPb16, RJt15, RHv15, RAu15, RNa16, RNz15, ROr15, 
RRb16, RSt15, RAk16, RUs15, RYe16, RVz15, RBn16 and RRn16. All proce-
dures were approved by the Emory University Institutional Animal Care 
and Use Committee (IACUC) and animal care facilities are accredited by 
the US Department of Agriculture and the Association for Assessment 
and Accreditation of Laboratory Animal Care International.
Rhesus macaques were infected intravenously with 3,000 TCID50 of 
SIVmac239 (nef open). SIVmac239 stock was titrated in vitro for viral infectiv-
ity by standard end-point titration on CEMx174 cells. The TCID50 was 
calculated using a previously published method34. All macaques were 
put on a three-drug ART regimen at 8 weeks after SIV infection. Teno-
fovir disoproxil fumarate (5.1 mg kg−1 per day or tenofovir, 20 mg kg−1 
per day) and emtricitabine (40 mg kg−1 per day) were both provided 
by Gilead Pharmaceuticals. Dolutegravir (2.5 mg kg−1 per day) was 
provided by ViiV Pharmaceuticals. Drugs were administered daily by 
subcutaneous injection.
After over 12 months of ART, macaques were assigned to intervention 
groups. Age, weight, sex, A01 status, peak post-infection viral load and 
time to suppression after ART were all controlled for when allocat-
ing macaques to intervention groups. Group sizes were determined 
using a power analysis based on previous studies. No blinding was 
performed in this study. One dose of the anti-CD8α-depleting antibody, 
MT807R1 (50 mg kg−1), was administered to 28 macaques. The initial 
15 macaques that received the depleting antibody received the admin-
istration intravenously. Owing to safety concerns, the administration 
was changed to subcutaneous for the remaining 13 macaques. There 
was no observable effect of the different administration routes on the 
efficacy of depletion.
At the start of the intervention, 21 macaques received a dose of N-803 
either in addition to CD8 depletion (n = 14) or as a single treatment 
(n = 7). N-803 was administered subcutaneously in a cycle of 100 μg kg−1 
once a week for 4 consecutive weeks.
The study design included a subsequent four-dose administration 
of N-803 in seven macaques of groups 1 and 2 that was carried out at 
the time of CD8+ T cell reconstitution to potentially accelerate the 
recovery of these cells and improve their antiviral cytotoxic potential. 
As expected, this second cycle of N-803 induced a faster recovery of 
CD8+ T cells (data not shown) and was associated with an increase in 
T cell activation and proliferation that was similar to the increased 
activation and proliferation observed after the first N-803 cycle (data 
not shown). The late administration did not result in an increase in 
plasma viraemia.
Macaques were interrupted of ART 3 weeks after either the last dose 
of N-803 or 3 weeks after the reconstitution of CD8+ T cells (whichever 
occurred first). Plasma viral loads were monitored for about 6 months 
until necropsy was performed.
CD8 depletion in combination with N-803 treatment in SHIV-
infected ART-treated macaques (pilot study)
An additional five Indian-origin rhesus macaques were included in 
this study as part of a follow-up pilot study using a SHIV model of 
infection. These macaques were also housed at the Yerkes National 
Primate Research Center and all procedures were approved by the 
Emory University IACUC. Macaques were infected intrarectally with 
high-dose SHIVSF162P3, administered as a 1:50 dilution of a 2,032 TCID50 
per ml, 109 RNA copies per ml, 182 ng ml−1 P27 stock. All macaques were 
placed on the same tenofovir, emtricitabine and dolutegravir ART 
regimen 12 weeks after SHIV infection. After 6 months of ART, macaques 
received one dose of MT-807R1 at 50 mg kg−1 subcutaneously. N-803 
was administered subcutaneously in a cycle of 100 μg kg−1 once a week 
for 4 consecutive weeks starting at the time of CD8 depletion.
Collection and processing of tissues from macaques
Blood, lymph nodes and rectal biopsies were collected longitudinally 
including at the time of necropsy and processed for further analyses 
as previously described18.
Immunophenotypes of macaques by flow cytometry
Multiparametric flow cytometry was performed according to a stand-
ard protocol on PBMCs and lymph node mononuclear cells using flu-
orescently labelled monoclonal antibodies cross-reactive in rhesus 
macaques. The following antibodies were used at 37 °C for 30 min: 
CCR5 APC (BD Biosciences, 560748, clone 3A9) and CCR7 FITC (BD 
Biosciences, 561271, clone 150503), in addition to LIVE/DEAD aqua 
viability dye (ThermoFisher, L35957) . The following antibodies were 
subsequently used at room temperature for 30 min: CD3 APC-Cy7 (BD 
Biosciences, 557757, clone SP34-2), CD4 BV650 (Biolegend, 317436, 
clone OKT4), CD8α BV711 (Biolegend, 301044, clone RPA-T8), pure 
CD8β (Thermo, 14-5273-82, clone SIDI8BEE) conjugated to Pe-Cy5 via 
a kit (Innova Biosciences, 760-0010), CD45RA Pe-Cy7 (BD Biosciences, 
561216, clone 5H9), CD62L PE (BD Biosciences, 341012, clone SK11), 
CD95 BV605 (Biolegend, 305628, clone DX2), PD-1 BV421 (Biolegend, 
329920, clone EH12.2H7), CD16 BV421 (BD Biosciences, 562874, clone 
3G8), CD20 PE-Cy5 (BD Biosciences, 555624, clone 2H7), CD14 PE-Cy7 
(BD Biosciences, 557742, clone M5E2), NKG2A (also known as CD159) 
PE (Beckman Coulter, IM3291U, clone Z199), CD28 PE-Cy5.5 or ECD 
(Beckman Coulter, B24027 and 6607111, respectively, clone CD28.2), 
CD56 FITC (BD Biosciences, 340723, clone NCAM16.2). Additional pan-
els included CD69 Pe-Cy5 (BD Biosciences, 555532, clone FN50) and 
CD25 APC (BD Biosciences, 555434, clone M-A251). Cells stained for 
Ki-67 were fixed and permeabilized with Perm II kit (BD Biosciences) 
before staining at room temperature for 30 min with Ki-67 AF700 (BD 
Biosciences, 561277, clone B56).
All flow cytometry specimens were acquired on an LSR II (BD Bio-
sciences) equipped with fluorescence-activated cell sorting (FACS) 
software (FACS Diva), and analysis of the acquired data was performed 
using FlowJo software (TreeStar).
Determination of plasma SIV RNA, and cell-associated RNA and 
DNA
For pre-intervention time points, quantitative PCR with reverse tran-
scription (RT–qPCR) was performed to determine SIV plasma viral 
load as previously described23 with a sensitivity of 60 copies per ml. 
For the three time points before intervention and all post-intervention 
time points, plasma SIV gag RNA levels were measured high-sensitivity 
assay formats24–26. Quantification of total cell-associated SIVmac239 gag 
DNA was performed as previously described35. The number of gag DNA 
copies per 106 CD4+ T cells was calculated by dividing the number of 
gag DNA copies per 106 PBMCs by the percentage of CD3+CD8−CD4+ 
cells in the PBMC population. CD4+ T cells were isolated from PBMCs 
using a CD4+ T cell isolation kit (Miltenyi) and cell-associated RNA was 
measured as previously described36.
In situ RNA analysis and quantification
Viral RNA (vRNA) detection using RNAscope and quantitative image 
analysis was performed on formaldehyde-fixed, paraffin-embedded 
tissue sections (5 μm) as previously published37, with the following 
minor modifications: heat-induced epitope retrieval was performed 
by boiling slides in 1× target retrieval (322000; ACD) for 30 min, fol-
lowed by incubation at 40 °C with a 1:10 dilution of protease III (322337; 
ACD) in 1× PBS for 20 min. Slides were incubated with the target probe 
SIVmac239 (312811; ACD) for 2 h at 40 °C and amplification was performed 
with RNAscope 2.5 HD Detection kits (322360; ACD) according to the 
manufacturer’s instructions, with 0.5× wash buffer (310091; ACD) 
used between steps. The resulting signal was detected with Warp Red 
chromogen (WR806M; Biocare Medical). Slides were counterstained 
with CAT haematoxylin (CATHE-GL; Biocare Medical), mounted with 
Clearmount (17885-15; EMS) until dry, after which a coverslip was added 
and sealed using Permount (SP15-100; Fisher Scientific). Slides were 
scanned at 40× magnification on an Aperio AT2 (Leica Biosystems). 
RNAscope images were analysed for the total number of vRNA+ cells per 
105 total cells (quantitative) and the relative amount of vRNA present 
(semiquantitative) using the ISH module (v.2.2) within the Halo software 
(v.2.3.2089.27; Indica Labs). The relative amount of vRNA within a single 
cell was first estimated by quantifying the total area of the vRNA signal 
spot size (μm2). As the signal spot size is a function of several steps in 
the experimental procedures, module settings were established on 
concomitantly assayed, acutely infected SIV+ control slides. To estimate 
the signal spot size of a single vRNA molecule, we measured the signal 
area (minimum, mean and maximum) of more than 10 identifiable indi-
vidual virions within B cell follicles, which corresponds to two copies of 
vRNA, and multiplied this by 0.5. We set the vRNA minimum signal spot 
size within the analysis module to exclude detection of a single vRNA 
molecule and/or integrated viral DNA. Relative vRNA copy numbers 
that were present within vRNA+ cells were calculated as (signal spot size 
within vRNA+ cell (μm2))/(0.5 × mean signal size for a virion).
FACS of live cells from macaques
Mononuclear cells isolated from blood were stained with LIVE/DEAD 
aqua viability dye (ThermoFisher, L35957), CD3 AF700 (BD Biosciences, 
557917, clone SP34-2), CD4 BV650 (Biolegend, 317436, clone OKT4), 
CD8 APC-Cy7 (BD Biosciences, 557834, clone SK1), CD14 PB (Biolegend, 
301828, clone M5E2), CD20 PB (Biolegend, 302328, clone 2H7) and CD16 
BV421 (Biolegend, 302032, clone 3G8) for 30 min at room temperature. 
Aliquots of 50,000 CD4+ T cells (live CD3+CD20−CD14−CD16−CD8−CD4+) 
and CD8+ T cells (live CD3+CD20−CD14−CD16−CD4−CD8+) were then 
sorted using a FACS Aria II (BD Biosciences). Mononuclear cells were 
separately stained with Live/Dead stain, CD3 AF700 (BD Biosciences, 
557917, clone SP34-2), CD4 BV650 (Biolegend, 317436, clone OKT4), 
CD8 APC-Cy7 (BD Biosciences, 557834, clone SK1), CD14 PB (Biolegend, 
301828, clone M5E2), CD20 PB (Biolegend, 302328, clone 2H7) and 
NKG2A PE (Beckman Coulter, IM3291U, clone Z199) to sort aliquots of 
50,000 NK cells (live CD3−CD20−CD14−CD4−CD8+NKG2A+).
RNA sequencing and data analysis
Bulk CD4+ T cells were sorted from fresh PBMCs before intervention, 
and on day 3, week 2 and week 4 post-intervention. In brief, RNA from 
sorted cells was collected and extracted, and the DNA was digested. 
Libraries were prepared and normalized, pooled and clustered on a 
flow cell for sequencing. RNA-sequencing data were aligned to the 
MacaM v.7.8 assembly of the Indian rhesus macaque genome. To iden-
tify pathways that were differentially modulated, gene-set enrichment 
analysis38 was performed on the ranked transcript lists using 1,000 
phenotype permutations and random seeding. Gene sets used included 
the MSigDB H (hallmark) gene sets39. Normalized enrichment scores 
for select upregulated gene sets were used, for which the normaliza-
tion was group-specific. A normalized enrichment score cut-off of 
greater than 1.35 for upregulated gene sets with a false-discovery rate 
of less than 0.2 was used, as per the recommendations for gene-set 
enrichment analysis. For the generation for heat maps, colours repre-
sent log2-transformed library-size-normalized read counts scaled to 
unit variance across transcript vectors and normalized to the baseline 
median sample value of each transcript.
Single-genome PCR amplification of SIVmac239 env sequences
cDNA synthesis and 384-well single-genome PCR amplification (SGA) 
were performed using an approach similar to previously described 
methods40–42. In brief, RNA was extracted from cryopreserved plasma 
samples using the QIAmp viral RNA kit (Qiagen, 52906) and reverse 
transcription was performed using the SuperScript III kit (Invitrogen, 
18080-044) with reverse primer SM-ER1 (5′-CTATCACTGTAATAAATCC-
CTTCCAGTCCC-3′). cDNA was diluted to result in less than 30% positive 
wells for SGA. First-round PCR was performed in a 15-μl volume using 
the Phusion Hotstart II High Fidelity DNA Polymerase (Thermo Scien-
tific, F537S) with forward primer H2SM-EF1 (5′-CCCTTGAAGGMGCM-
RGAGAGCTCATTA-3′) and SM-ER1. Cycling conditions were as follows: 
98 °C for 2 min; 10 cycles of 95 °C for 15 s, 54 °C for 60 s and 68 °C for 
4 min; 25 cycles of 95 °C for 15 s, 54 °C for 60 s and 68 °C for 4 min, 
adding 5 s to the extension per cycle; 72 °C for 30 min; and 4 °C hold. 
Second-round PCR was performed with the same enzyme in a 10-μl 
volume with 1 μl of the first-round PCR reaction as template and primers 
H2SM-EF2 (5′-CACCTAAAAARTGYTGCTAYCATTGCCAG-3′) and SM-ER2 
(5′-ATAAAATGAGACATGTCTATTGCCAATTTG-3′). Cycling conditions 
were as follows: 95 °C for 2 min; 30 cycles of 95 °C for 15 s, 54 °C for 60 s 
and 72 °C for 2.5 min; 72 °C for 10 min; and 4 °C hold. PCR amplicons 
were purified using a Qiaquick PCR Purification Kit (Qiagen 28106).
Sequencing of env amplicons
On average, 26 SGA PCR amplicons per time point (range, 20–30) were 
sequenced by Eurofins Genomic DNA Sanger sequencing using the 
following primers: SIVmac251seqF1 5′-GGGATATGTTATGAGCAGT-
CACG-3′; SIVmac251seqF2 5′-ATCCAAGAGTCTTGTGACAAGC-3′; 
SIVmac251seqF3 5′-AAGAGAGGGAGACCTCACG-3′; SIVmac251seqF4 
5′-AGGCCAGTGTTCTCTTCC-3′; SIVmac251seqR1 5′-CTTGTTCCAA-
GCCTGTGC-3′; SIVmac251seqR2 5′-CCTCTGCAATTTGTCCACATG-3′; 
SIVmac251seqR3 5′-TCCAAGAAGTCAACCTTTCGC-3′; SIVmac251seqR4 
5′-AGCTGGGTTTCTCCATGG-3′18. Sequencher v.5.1 was used to generate 
nucleotide sequence contigs and sequences with mixed peaks in the 
chromatogram were excluded from further analysis.
Sequence analysis of SIVmac239 contigs
Geneious v.9.1.7 was used to translate nucleotide sequences into amino 
acids and generate alignments. Amino acid alignments were exported 
from Geneious in FASTA format and used to generate highlighter 
plots to visualize amino acid mismatches (http://www.hiv.lanl.gov/
content/sequence/HIGHLIGHT/highlighter_top.html). Phylogenetic 
neighbour-joining consensus trees ( Jukes–Cantor, resampling with 
100 bootstrap replicates) were created in Geneious using amino acid 
alignments, and were exported in NEXUS format into Figtree v.1.4.4 
for further modification (A. Rambaut, http://tree.bio.ed.ac.uk/). Phy-
logenetic trees were presented as unrooted or were rooted on the 
midpoint. Bootstrap values that were higher than 80% are considered 
significant. Pairwise differences between the infecting SIVmac239 clone 
and each SGA-derived Env amino acid sequence were determined 
using Geneious.
Experimental design of the BLT humanized mouse model
The BLT humanized model of HIV infection was used to determine the 
efficacy of CD8 depletion alone, CD8 depletion in combination with 
N-803 or N-803 alone as a LRA. BLT mice (15–19 weeks after humaniza-
tion surgery) were exposed to HIV-1JR-CSF intravenously. ART was initiated
4–5 weeks later. Viraemia was durably suppressed by ART for 4 weeks. 
A single dose of N-803, CD8-depleting antibody or the combination of 
N-803 and CD8-depleting antibody was administered to HIV-infected 
and suppressed mice as indicated below. HIV RNA induction was meas-
ured on days 4 and 7.
Generation of BLT humanized mice
BLT humanized mice were prepared as previously reported43–46. In 
brief, a 1–2-mm piece of human liver tissue was sandwiched between 
two pieces of autologous thymus tissue (Advanced Bioscience 
Resources) under the kidney capsule of sublethally irradiated (200 cGy) 
12–15-week-old NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG; The Jackson Labo-
ratory) mice. After implantation, mice were transplanted intravenously 
with haematopoietic CD34+ stem cells isolated from autologous human 
liver tissue. Human immune cell reconstitution was monitored in the 
peripheral blood of BLT mice by flow cytometry every 3–4 weeks as 
previously described43–46. Mice were maintained under specific-path-
ogen-free conditions by the Division of Comparative Medicine at the 
University of North Carolina, Chapel Hill. Mouse experiments were 
conducted in accordance with NIH guidelines for the housing and care 
of laboratory animals and in accordance with protocols reviewed and 
approved by the IACUC at the University of North Carolina, Chapel Hill.
Production of HIV and infection of BLT mice
Stocks of HIV-1JR-CSF were prepared as previously reported
43–45. The pro-
viral clone was transfected into human embryonic kidney (HEK)293T 
cells using Lipofectamine 2000 (Invitrogen, 11668030) following the 
manufacturer’s protocol. Viral supernatants were collected 48 h after 
transfection and titred onto TZM-bl indicator cells in triplicate to deter-
mine the tissue-culture infectious units (TCIU) per ml. At least two 
different titre determinations were performed for each virus stock. 
BLT mice were exposed to 3 × 104 TCIU HIV-1JR-CSF by tail-vein injection.
Analysis of HIV infection in BLT mice
The peripheral-blood plasma viral load was monitored longitudinally by 
quantitative real-time PCR using a TaqMan RNA-to-Ct 1-step kit (Applied 
Biosystems, 4392656). The sequences of the forward and reverse prim-
ers and the TaqMan probe for PCR amplification and detection of HIV 
gag RNA were: 5′-CATGTTTTCAGCATTATCAGAAGGA-3′, 5′-TGCTT-
GATGTCCCCCCACT-3′ and 5′-FAM-CCACCCCACAAGATTTAAACAC-
CATGCTAAQ-3′, respectively. Known quantities of HIV gag RNA were 
run in parallel, creating a standard curve for HIV gag and sample RNA 
levels were quantified by extrapolation from the standard curve. All 
samples were run and analysed on an ABI 7500 Fast Real-time PCR Sys-
tem (Applied Biosystems).
HIV DNA levels were measured in tissue cells collected at the time 
of collection and cryopreserved in cryopreservation medium (10% 
DMSO:90% fetal bovine serum). Cells were thawed slowly, counted 
by Trypan exclusion, aliquoted and pelleted. DNA was extracted from 
cell pellets using the QIAamp DNA Blood Mini Kit (Qiagen) accord-
ing to the manufacturer’s instructions. RT–PCR was performed with 
a TaqMan Fast Universal PCR Master Mix (Applied Biosystems). The 
sequences of the forward primer, reverse primer and the TaqMan 
probe for amplification and detection of HIV gag DNA were: 5′-CAT-
GTTTTCAGCATTATCAGAAGGA-3′, 5′-TGCTTGATGTCCCCCCACT-3′ and 
5′-FAM CCACCCCACAAGATTTAAACACCATGCTAA Q -3′, respectively. 
As a control, Homo sapiens haemoglobin subunit gamma-2 (HBG2) 
was included to quantify the presence of human DNA in each sample. 
The sequences of the forward primer, reverse primer and the TaqMan 
probe for amplification and detection of HBG2 were 5′-CGCTTCTG-
GAACGTCTGAGATT-3′, 5′-CCTTGTCCTCCTCTGTGAAATGA-3′ and 
5′-FAM-TCAATAAGCTCCTAGTCCAGAC-3′, respectively. All samples 
were run and analysed on an ABI 7500 Fast Real-time PCR System 
(Applied Biosystems).
ART administration in BLT mice
ART was administered to BLT humanized mice   as previously 
described47–49, via 12.7-mm pellets of irradiated Teklad chow con-
taining emtricitabine (1,500 mg kg−1), tenofovir disoproxil fumarate 
(1,560 mg kg−1) and raltegravir (600 mg kg−1) (Research Diets).
N-803 and MT807R1 administration in BLT mice
N-803 (0.2 mg kg−1 in PBS) and the control vehicle (PBS) were admin-
istered to mice intravenously in a total volume of 200 μl. MT807R1
(3 mg kg−1 in PBS) and the control vehicle (PBS) were also administered 
intravenously in a total volume of 200 μl.
Immunophenotypic analysis of BLT mice
Immunophenotyping was performed on peripheral-blood samples 
longitudinally and at the time of collection on blood and mononuclear 
cells isolated from the tissues of BLT mice. All flow cytometry data were 
collected on a BD FACSCanto instrument using BD FACSDiva software 
(v.6.1.3) and data were analysed with FlowJo Software (v.10.5.0). Anti-
bodies for the analysis of human immune cell levels included: CD45 
APC (BD 555485, clone HI30), CD3 FITC (BD Biosciences, 555339, clone 
HIT3a), CD4 APC-Cy7 (BD Biosciences, 560158, clone RPA-T4), CD33 PE 
(BD Biosciences, 340679, clone P67.6); CD19 PE-Cy7 (BD Biosciences, 
557835, clone SJ25C1) and CD8 PerCP (BD Biosciences, 347314, clone 
SK1). Flow cytometry gating for the expression of lineage-specific anti-
gens on human leukocytes was performed as follows. Step 1, forward 
and side scatter were used to set a live-cell gate. Step 2, live cells were 
then analysed for the expression of the human pan-leukocyte marker 
CD45. Step 3, human leukocytes were then analysed for human CD3+ 
T cells and CD19+ B cells. Step 4, T cells were analysed for human CD4 
and CD8 expression. The following flow cytometry antibody panel was 
also used to analyse HLA-DR, CD38 and CD25 expression: CD3 BV421 
(BD Biosciences, 562426, clone UCTH1), CD4 BV605 (BD Biosciences, 
562658, clone RPA-T4), CD45 FITC (BD Biosciences, 347463, clone 2D1), 
HLA-DR PerCP (BD Biosciences, 347364, clone L243), CD69 PE (BD 
Biosciences, 555531, clone FN50), anti-CD38 PE-Cy7 (BD Biosciences, 
335790, clone HB7), CD25 APC (BD Biosciences, 340938, clone 2A3), 
CD8 APC-Cy7 (BD Biosciences, 557834, clone SK1) and AQUA (Ther-
moFisher, L35957). Flow cytometry gating was performed as follows. 
Step 1, forward-scatter height and forward-scatter area were used to 
eliminate doublets. Step 2, side-scatter area and forward-scatter area 
were used to distinguish leukocytes based on morphology. Step 3, the 
viability dye AQUA was use to discriminate live cells from dead cells. 
Step 4, live cells were analysed for the expression of the human pan-
leukocyte marker CD45. Step 5, human leukocytes were then assessed 
for human CD3 expression to identify T cells. Step 6, T cells were evalu-
ated for the expression of human CD4 and CD8. Step 7, human CD4+ 
or CD8+ T cells were examined for expression of HLA-DR and/or CD38, 
or CD25. Gates were set with fluorescence-minus-one controls. Non-
specific binding was assessed with isotype controls.
Experimental design CD8 in vitro suppression assay
In vitro latently infected memory CD4+ T cells were generated using the 
LARA method as previously described32 with the following modifica-
tions. On day 0, after PBMCs were isolated from buffy coats of HIV-naive 
individuals (New York Blood Center) using SepMate density-gradient 
centrifugation (StemCell Technologies, 85460), a portion of PBMCs 
from each HIV-naive donor was cryopreserved in fetal bovine serum 
(VWR Life Science Seradigm, 97068-085) and 10% DMSO, and stored in 
liquid nitrogen. On day 8, PBMCs were thawed and rested overnight in 
RPMI 1640 medium (Fisher Scientific, SH3002701.01) supplemented 
with 10% fetal bovine serum, 1% penicillin–streptomycin (Corning, 
45000-650), and 1% HEPES (Gibco, 15630080); cRPMI) before total 
CD8+ T-cell-positive enrichment on day 9 (Miltenyi, 130-045-201). CD8+ 
T cells were stimulated with anti-CD3/CD28 beads (Dynabeads, 11141D) 
at a 1:1 ratio plus 30 U ml−1 IL-2 (R&D Systems, 202IL050CF) for 3 days. 
On day 12 of LARA, CD4+ and CD8+ were prepared for co-culture. HIV 
latently infected memory CD4+ T cells were washed, counted and plated 
for latency reversal in cRPMI in the presence of ART (100 nM efavirenz, 
200 nM raltegravir and 5 μM saquinavir). Activated total CD8+ T cells 
were removed from the anti-CD3/CD28 beads, washed and resuspended 
in cRPMI plus ART. CD4+ and CD8+ T cells were co-cultured at a 1:1 or 
1:5 ratio at a final density of 1 × 106 cells per ml. CD4+ monocultures 
were also maintained in parallel. Mono- and co-cultures were then 
left unstimulated, TCR-activated with 1 μg ml−1 plate-bound OKT3 and 
1 μg ml−1 soluble CD28 (Biolegend, 302933), or treated with 14 nM N-803 
(provided by NantKwest) or 500 ng ml−1 IL-15 (R&D Systems, 247-ILB). 
Cells were collected after 72 h and analysed by flow cytometry and 
qPCR.
Multicolour flow analysis of cell-surface and intracellular marker 
expression was performed with a BD FACSymphony flow cytometer. 
Between 200,000 and 600,000 events were acquired for each sample 
using the live-cell gate. The data were analysed with FlowJo (v.10).
Antibodies used in in vitro suppression assays include: CD3 AF700 
(BD Biosciences, 557943, clone UCHT1), CD8 BUV737 (BD Biosciences, 
564629, clone SK1), HIV-1 core antigen-FITC (Beckman Coulter, 
6604665, clone KC57), CD4 BV421 (BD Horizon, 565997, clone SK3), 
CD45RA APC-eFluor780 (Invitrogen, 47045842, clone HI100), CD27 
BV650 (Biolegend, 302828, clone O323), CCR7 Pe-Cy7 (BD Pharmingen, 
557648, clone 3D12) and Fixable Viability Dye eFluor 506 (Invitrogen 
eBioscience, 65-0866-18).
Statistics and reproducibility
Statistical analyses, including two-way Kruskal–Wallis tests, two-way 
Friedman tests, one-way ANOVA and Spearman r correlations, were 
performed using GraphPad Prism v.7.0 or v.8.0. Data are mean ± s.e.m. 
as indicated.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
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Extended Data Fig. 1 | MT807R1 effectively depletes CD8+ T cells in 
peripheral blood, lymph node and rectum of macaques in addition to 
depleting NK cells from the blood at day 7. The percentage of CD8+ cells in the 
CD3+ population 7 days after depletion was compared to the levels before 
depletion. a–c, Sample flow cytometry shows the absence of CD8β+ cells as 
part of the CD3+ T cell population after depletion in the peripheral blood (a), 
rectum (b) and lymph nodes (c) of macaques. Similar results were found across 
all CD8-depleted macaques (n = 28 biologically independent samples). d, The 
percentage of CD8β+ cells compared to pre-depletion baseline was calculated 
in all CD8-depleted macaques (treated with or without N-803, n = 28 macaques) 
across blood and tissue samples (no differences in CD8+ T cell depletion were 
observed between groups 2 and 3 on day 7). A two-sided Friedman test was used 
to calculate statistically significant changes compared to baseline across 
tissues. e, Depletion of NK cells in the peripheral blood was assessed 1 week 
after CD8 depletion alone (n = 14 macaques) compared to baseline. Statistical 
significance was calculated using Wilcoxon signed-rank test. Data are 
mean ± s.e.m.
Extended Data Fig. 2 | Phenotypic changes to CD4+ T cells after intervention. 
Longitudinal flow cytometry analysis after treatment with only N-803 (green, 
n = 7 macaques), only CD8 depletion (blue, n = 14 macaques) and after CD8 
depletion and treatment with N-803 (red, n = 14 macaques). a, CD4+ T cell 
frequency. b–f, Percentage of naive (b), stem cell memory (SCM) (c), central 
memory (CM) (d), transitional memory (TM) (e) and effector memory (EM) (f) 
CD4+ T cells. g–l, Percentage of bulk CD4+ T cells that express PD-1 (g), CD25 (h), 
CD69 (i), HLA-DR ( j), CCR5 (k) and both CCR5 and Ki-67 (l). m–v, CCR5 (m–q) 
and Ki-67 (r–v) expression in different subsets of CD4+ T cells. Data are 
mean ± s.e.m. Two-sided Kruskal–Wallis tests were used to compare values 
after the intervention to the pre-intervention baseline and approximate P-
value summaries are provided.
Extended Data Fig. 3 | SIV-associated genes and IL-15 subunit genes show a 
transient change in expression after treatment with N-803 alone. RNA was 
extracted from sorted peripheral bulk CD4+ T cells (CD3+CD4+CD8−CD20−
CD14−) (left), bulk CD8+ T cells (CD3+CD4−CD8+CD20−CD14−) (middle) and NK 
cells (CD3−CD20−CD14−NKG2A+) (right) and libraries were prepared, 
normalized, pooled and clustered on flow cells for sequencing. RNA-
sequencing data were aligned to the MacaM v.7.8 assembly of the Indian rhesus 
macaque genome. Transcripts were analysed for alignment against a custom 
gene set with SIV host restriction factors, PPIA (capsid folding protein), SIV 
receptors, SIV receptor agonists, NF-κB subunits (involved in mediating the 
transcription of long-terminal repeat regions), IL-15 receptor subunits and 
NFAT subunits. D, day; W, week.
Extended Data Fig. 4 | Quantification of levels of cell-associated SIV RNA in 
peripheral CD4+ T cells before and after interventions. a–c, Changes in 
expression of SIV RNA in relation to the number of copies of CD4 after 
intervention with N-803 alone (n = 7 macaques) (a), CD8 depletion alone 
(n = 7 macaques) (b) or CD8 depletion combined with N-803 
(n = 7 macaques) (c). Data are mean ± s.e.m. Two-sided Wilcoxon signed-rank 
tests were used to compare values after the intervention to the pre-
intervention baseline.
Extended Data Fig. 5 | Level of virus reactivation correlated with the absence 
of CD8+ T cells. a, b, Correlation between CD8+ T cell counts and viral load (SIV 
RNA copies per ml of plasma) on day 0, day 3, and weekly up to week 6 after 
interventions. a, CD8 depletion alone (n = 103 samples from 14 macaques).  
b, CD8 depletion combined with N-803 treatment (n = 112 samples from 
14 macaques). c, d, The area under the curve (AUC) and the average pre-
intervention viral load after CD8 depletion alone (c; n = 14 macaques) or CD8 
depletion with N-803 treatment (d; n = 14 macaques). Correlation coefficients 
are calculated using the Spearman’s rank-order correlation (two-tailed, no 
adjustments). e–g, Longitudinal viral loads (top) and CD8+ T cell counts 
(bottom) after N-803 treatment alone (e; n = 7 macaques), CD8 depletion alone 
(f; n = 14 macaques) or CD8 depletion combined with N-803 treatment (g; n = 14 
macaques). Colour keys along the bottom indicate animal IDs.
Extended Data Fig. 6 | HIV DNA, HIV RNA and human T cell activation levels 
in HIV-infected, ART-suppressed BLT humanized mice treated with N-803, 
CD8 depletion alone or combined CD8 depletion with N-803 . a, b, HIV-
infected, ART-suppressed BLT humanized mice were treated with N-803 
(green, n = 4 BLT humanized mice), CD8 depletion alone (blue, n = 4), or treated 
with CD8 depletion with N-803 (red, n = 4). After 7 days, total HIV DNA (a) and 
cell-associated HIV RNA (b) were extracted from mononuclear cells isolated 
from the spleen, human-derived thymus (huThy) and lymph node (LN; HIV RNA 
only). c–f, Percentages of HLA-DR+, CD38+, CD25+ or HLA-DR+CD38+ cells were 
measured in human CD4+ (c, e) or CD8+ (d, f) T cells isolated from the spleen  
(c, d) or human-derived thymus (e, f) of HIV-infected, ART-suppressed BLT 
humanized mice 7 days after treatment with N-803 (green, n = 4), CD8 depletion 
alone (blue, n = 4) or CD8 depletion combined with N-803 treatment (red, n = 4). 
Treatment groups were compared using a two-tailed Student’s t-test (a) or a 
Kruskal–Wallis test with a false-discovery rate correction (b–f). Data are 
mean ± s.e.m.
Extended Data Fig. 7 | Phylogenetic trees of longitudinal SGA-derived Env 
amino acid sequences. Phylogenetic trees were generated for six macaques 
that received CD8 depletion with N-803 using Env sequences from the peak 
viral load (red), pre-ART (blue) and reactivation (green) time points. The Env 
sequence of the SIVmac239 clone used for infection is included in each tree 
(black). The horizontal bar below each tree indicates the genetic distance. 
Sequence clusters that are supported by bootstraps greater than 80% are 
indicated by an asterisk. Env sequences that contain a stop codon are indicated 
by an arrow.
Extended Data Fig. 8 | Longitudinal Env amino acid divergence from the 
input virus and relationship with viral load in the plasma. The number of 
amino acid differences between the infecting viral clone SIVmac239 and each SGA 
amplicon was determined using Geneious. a, Violin plots show the frequency 
distribution of the number of amino acid differences between sequences at 
each time point in each macaque. The solid line indicates the median number of 
amino acid differences for each individual Env sequence; the dotted lines 
indicate the quartiles. Peak viral load (VL) (red), pre-ART (blue) and 
reactivation (green) time points are shown. The animal ID and the three time 
points are indicated on the x axis. Statistical differences between time points 
for each macaque were determined by performing multiple comparisons using 
a Kruskal–Wallis test with Dunn’s correction. b, The average number of 
sequence differences for each macaque at the reactivation time point is 
plotted on the y axis, and the corresponding plasma viral loads are plotted on 
the x axis on a log10 scale. Correlation coefficients are calculated using the 
Spearman’s rank-order correlation (two-tailed, no adjustments).
Extended Data Fig. 9 | Highlighter plots of longitudinal SGA-derived Env 
amino acid sequences. Highlighter plots were generated for six representative 
macaques that were depleted of CD8 and treated with N-803 using Env 
sequences from peak VL (red box), pre-ART (blue box) and reactivation (green 
box) time points. The Env sequence of the SIVmac239 clone used for infection is 
included as the master (reference) sequence in each plot. The position of N-
linked glycosylation sites on the master sequence are indicated by pink circles. 
Each tick represents an amino acid difference from the master sequence, as 
indicated in the key. Blue diamonds indicate the loss of an N-linked 
glycosylation site.
Extended Data Table 1 | Viral loads from macaque and humanized mouse studies
Longitudinal viral loads before and after interventions using the ART-treated, SIVmac239-infected rhesus macaque model (limit of detection of three copies of SIV RNA per ml of plasma; corre-
sponding to Fig. 2a–d) (top), the ART-treated, SHIVSF162P3-infected rhesus macaque model (limit of detection of 3 copies of SHIV RNA per ml of plasma; corresponding to Fig. 2g) (middle) and the 
ART-treated, HIVJR-CSF-infected BLT humanized mouse model (limit of detection of 346 copies of HIV RNA per ml of plasma; corresponding to Fig. 2i–k) (bottom).
